Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - A comparison with immunohistochemical and FISH results

Pathology and Oncology Research

Volumn 12, Issue 4, 2006, Pages 197-204

  Kulka, Janina ^a   Tokés, Anna Mária ^a   Kaposi Novák, Pál ^a   Udvarhelyi, Nóra ^b   Keller, Anikó ^a   Schaff, Zsuzsa ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Breast carcinoma; FISH; HER 2 neu DNA amplification; HER 2 neu protein; Immunohistochemistry; LightCycler RT PCR system; Quantitative RT PCR

Indexed keywords

ANTIBODY; CB11 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY ANALYSIS;

EID: 33847043534     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893412     Document Type: Article

References (43)

1. Allred DC, Clark GM, Molina R, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992
2. Bánkfalvi A, Boecker W, Reiner A: Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using Ventana BenchMark automated staining system and manual tests. Int J Oncol 25: 929-935, 2004
3. Bánkfalvi A, Giuffre G, Ofner D, et al: Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis. Int J Oncol 23: 1285-1292, 2003
4. Bánkfalvi Á: HER-2 diagnostics. Magy Onkol 46: 11-15, 2002 [In Hungarian]
5. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986
6. Bartlett JM, Going JJ, Mallon EA, et al: Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195: 422-428, 2001
7. Beyser K, Reiser A, Gross C, et al: J. Real-time quantification of HER2/neu gene amplification by LightCycler Polymerase Chain Reaction (PCR) - a new research tool. Biochemica 2: 15-18, 2001
8. Beyser K, Reiser A, Gross C, et al: PCR is a powerful tool to assess HER2/neu positivity in breast cancer. Eur J Cancer 158: 419-429, 2001
9. Bilous M, Ades C, Armes J, et al: Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 international study. Breast 12: 92-98, 2003
10. DiGiovanna MP: Clinical significance of HER-2/neu overexpression: Part I. Principles and Practice of Oncology 13: 1-10, 1999
11. Elkin EB, Weinstein MC, Winer EP, et al: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22: 854-863, 2004
12. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 19: 403-410, 1991
13. Esteva FJ, Sahin AA, Smith TL, et al: Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100: 499-506, 2004
14. Gjerdrum LM, Sorensen BS, Kjeldsen E, et al: Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma. J Mol Diagn 6: 42-51, 2004
15. Gusterson BA, Machin LG, Gullick WJ, et al: Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer 42: 842-845, 1988
16. Hammock L, Lewis M, Phillips C, et al: Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 34: 1043-1047, 2003
17. Harbeck N, Ross JS, Yurdseven S, et al: HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node negative breast cancer. Int J Oncol 14: 663-671, 1999
18. Jacobs TW, Gown AM, Yaziji H, et al: HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry; a study of interlaboratory agreement. Am J Clin Pathol 113: 251-258, 2000
19. Jimenez RE, Wallis T, Tabasczka P, Visscher DW: Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13: 37-45, 2000
20. Kakar S, Puangsuvan N, Stevens JM, et al: HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 5: 199-207, 2000
21. Kauraniemi P, Hautaniemi S, Autio R, et al: Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 23: 1010-1013, 2004
22. Lebeau A, Deimling D, Kaltz C, et al: Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and in situ hybridization. J Clin Oncol 19: 354-363, 2001
23. Lopez-Guerrero JA, Navarro S, Noguera R, et al: Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. Arkh Patol 65: 50-55, 2003
24. Lu Y, Zi X, Zhao Y, Pollak M: Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem Biophys Res Commun 313: 709-715, 2004
25. Luftner D, Henschke P, Kafka A, et al: Discordant results obtained for different methods of HER-2/neu testing in breast cancer - a question of standardization, automation and timing. Int J Biol Markers 19: 1-13, 2004
26. Ma Y, Lespagnard L, Durbecq V, et al: Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11: 4393-4399, 2005
27. Nistor A, Watson PH, Pettigrew N, et al: Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol 6:2 doi:10.1186/1472-6890-6-2, 2006
28. O'Malley FP, Parkes R, Latta E, et al: Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 115: 504-511, 2001
29. Pavelic ZP, Pavelic L, Lower EE, et al: C-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 52: 2597-2606, 1992
30. Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77: 148-154, 2002
31. Press MF, Slamon DJ, Flom KJ, et al: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095-3105, 2002
32. Riben MW, Malfetano JH, Nazeer T, et al: Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 10: 823-831, 1997
33. Ridolfi RL, Jamehdor MR, Arber JM: HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13: 866-873, 2000
34. Ross JS, Fletcher JA: The HER2/neu (c-erbB-2) gene and protein in breast cancer. Am J Clin Pathol 112 (Suppl 1): 553-567, 1999
35. Seshadri R, Figaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936-1942, 1993
36. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
37. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
38. Somerville JE, Clarke LA, Biggart JD: C-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 45: 16-20, 1992
39. Suo Z, Daehli KU, Lindboe CF, et al: Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients. Int J Surg Pathol 12: 311-318, 2004
40. Taylor SL, Platt-Higgins A, Rudland PS, et al: Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer 76: 459-463, 1998
41. th European Breast Cancer Conference, Hamburg, 395, 2004
42. Van de Vijver M, Peterse JL, Mooi WJ, et al: Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239-1245, 1988
43. Woods Ignatoski KM, Grewal NK, Markwart S, et al: p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion. Neoplasia 5:128-134, 2003